Verastem Inc (VSTM) Stock Price, Quote & News

Company Profile

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 292 4200

Website: www.verastem.com

Address:

117 Kendrick Street, Suite 500, Needham, United States

AtomicAIerts Dec. 5 at 10:55 AM

$VSTM AtomicAlerts Scalp Alert Direction: LONG Entry: $10.59 TP1: $11.29 | TP2: $11.99 | TP3: $12.69 Stop Loss: $9.99 👉 https://atomicalerts.com

0 · Reply

CrozrX Dec. 5 at 10:19 AM

$VSTM 🎯 This is the first-in-world registrational clinical study of an oral KRAS G12D inhibitor for the treatment of pancreatic cancer!! 🔸️ http://www.genfleet.com/en/press_release-99

0 · Reply

Iightning Dec. 5 at 5:55 AM

1ightning® Premium Options Alert (Actionable) Ticker: $VSTM Contract: Dec 19 $11C Entry: 0.75 Exit: 1.00 Return: +32.74% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

beeelaaal Dec. 5 at 2:25 AM

$VSTM FDA approvals process would speed up with AI predicting phase 3 results from phase 2 data ? liberal yet right policy for republicans https://www.facebook.com/share/v/1Hvc99sCzX/?mibextid=wwXIfr

1 · Reply

Iightning Dec. 4 at 11:43 PM

1ightning® Premium Options Alert (Actionable) Ticker: $VSTM Contract: Dec 19 $11C Entry: 0.75 Exit: 1.00 Return: +32.74% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

SuperGreenToday Dec. 4 at 9:37 PM

$VSTM Share Price: $10.59 Contract Selected: Mar 20, 2026 $10 Calls Buy Zone: $1.87 – $2.31 Target Zone: $3.46 – $4.23 Potential Upside: 75% ROI Time to Expiration: 105 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

OneSmartBull Dec. 4 at 8:39 PM

$VSTM 50 EMA (yellow line)about to cross 200 EMA (blue line) = Golden Cross A 50 EMA cross 200 EMA is a technical analysis signal where the shorter-term 50-period exponential moving average (EMA) crosses the longer-term 200-period EMA. An upward cross, known as a "golden cross," suggests a long-term bullish trend, while a downward cross, called a "death cross," indicates a potential long-term bearish trend. Don't sleep on it

1 · Reply

DrTim Dec. 4 at 5:33 PM

$VSTM Why do people on this board keep talking about selling this company...for maybe twice the current share price??? Do you not realize the huge potential here? "IF" we should get approval for wild type ovarian cancer, that alone would double the share price. And if we get approval for PDAC, that would be an absolute game changer! One would be looking at an initial share price of a minimum $30-50. And all of this doesn't even take into consideration NSCLC and other potential cancer treatments. You do you but as for me, my goal is to see a SP of $20-30 and get bought out for a Minimum Multiple of 3-5X the share price.

3 · Reply

ChesterKaita Dec. 4 at 5:13 PM

$VSTM News after hiurs?

0 · Reply

Consti22 Dec. 4 at 4:52 PM

$VSTM Extrem>>>

0 · Reply

Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference

Nov 14, 2025, 12:41 AM EST - 21 days ago

Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 13, 2025, 4:07 PM EST - 21 days ago

Verastem Oncology Announces Proposed Public Offering of Common Stock

Nov 5, 2025, 7:30 AM EST - 4 weeks ago

Verastem Oncology to Present at Upcoming Investor Conferences

Nov 4, 2025, 10:16 AM EST - 4 weeks ago

Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 7:30 AM EST - 4 weeks ago

Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Oct 23, 2025, 4:01 PM EDT - 6 weeks ago

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors

Oct 23, 2025, 7:30 AM EDT - 6 weeks ago

Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025

Oct 19, 2025, 4:15 AM EDT - 6 weeks ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

Oct 7, 2025, 7:30 AM EDT - 2 months ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 13, 2025, 4:29 PM EDT - 4 months ago

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

Aug 8, 2025, 8:55 PM EDT - 4 months ago

Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 4 months ago

Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

Jul 29, 2025, 7:30 AM EDT - 4 months ago

Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 24, 2025, 7:30 AM EDT - 4 months ago

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer

Jul 16, 2025, 8:22 AM EDT - 5 months ago

Verastem: The Market Is Ignoring The Progress

Jul 11, 2025, 4:12 PM EDT - 5 months ago

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

Jun 30, 2025, 4:02 PM EDT - 5 months ago

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

Jun 26, 2025, 11:16 AM EDT - 5 months ago

Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers

Jun 24, 2025, 4:02 PM EDT - 5 months ago

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

Jun 2, 2025, 9:40 AM EDT - 6 months ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

May 28, 2025, 7:30 AM EDT - 6 months ago

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

May 22, 2025, 5:01 PM EDT - 7 months ago

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

May 20, 2025, 8:30 AM EDT - 7 months ago

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

TEM

May 13, 2025, 4:34 PM EDT - 7 months ago

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

May 8, 2025, 1:17 PM EDT - 7 months ago

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

May 8, 2025, 12:23 PM EDT - 7 months ago

U.S. FDA approves Verastem's cancer therapy

Apr 25, 2025, 9:00 AM EDT - 7 months ago

Verastem Oncology Announces $75 million Private Placement

Apr 23, 2025, 4:05 PM EDT - 8 months ago

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

Apr 10, 2025, 2:35 PM EDT - 8 months ago

Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination

Mar 25, 2025, 4:35 PM EDT - 9 months ago

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

Mar 20, 2025, 4:01 PM EDT - 9 months ago

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Feb 20, 2025, 4:05 PM EST - 10 months ago

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Jan 29, 2025, 7:30 AM EST - 11 months ago

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Jan 23, 2025, 7:30 AM EST - 11 months ago

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Jan 15, 2025, 7:30 AM EST - 11 months ago

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

Jan 14, 2025, 7:30 AM EST - 11 months ago

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Jan 13, 2025, 7:30 AM EST - 11 months ago

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

Jan 3, 2025, 11:56 AM EST - 11 months ago

Verastem: Planning The PDUFA Run-Up

Jan 2, 2025, 11:39 AM EST - 1 year ago

Verastem: BLA Acceptance Puts Key Goals In Sight

Dec 31, 2024, 10:59 AM EST - 1 year ago

Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday?

Dec 30, 2024, 4:30 PM EST - 1 year ago

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Dec 18, 2024, 7:30 AM EST - 1 year ago

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Nov 27, 2024, 1:28 PM EST - 1 year ago

Verastem: Preparing For Upcoming Catalysts

Nov 26, 2024, 7:00 AM EST - 1 year ago

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

Nov 6, 2024, 4:05 PM EST - 1 year ago

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Oct 31, 2024, 4:01 PM EDT - 1 year ago

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Verastem Oncology to Participate in Upcoming Investor Conferences

Oct 17, 2024, 1:00 AM EDT - 1 year ago

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting

Oct 9, 2024, 6:00 AM EDT - 1 year ago

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

AtomicAIerts Dec. 5 at 10:55 AM

$VSTM AtomicAlerts Scalp Alert Direction: LONG Entry: $10.59 TP1: $11.29 | TP2: $11.99 | TP3: $12.69 Stop Loss: $9.99 👉 https://atomicalerts.com

0 · Reply

CrozrX Dec. 5 at 10:19 AM

$VSTM 🎯 This is the first-in-world registrational clinical study of an oral KRAS G12D inhibitor for the treatment of pancreatic cancer!! 🔸️ http://www.genfleet.com/en/press_release-99

0 · Reply

Iightning Dec. 5 at 5:55 AM

1ightning® Premium Options Alert (Actionable) Ticker: $VSTM Contract: Dec 19 $11C Entry: 0.75 Exit: 1.00 Return: +32.74% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

beeelaaal Dec. 5 at 2:25 AM

$VSTM FDA approvals process would speed up with AI predicting phase 3 results from phase 2 data ? liberal yet right policy for republicans https://www.facebook.com/share/v/1Hvc99sCzX/?mibextid=wwXIfr

1 · Reply

Iightning Dec. 4 at 11:43 PM

1ightning® Premium Options Alert (Actionable) Ticker: $VSTM Contract: Dec 19 $11C Entry: 0.75 Exit: 1.00 Return: +32.74% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

SuperGreenToday Dec. 4 at 9:37 PM

0 · Reply

OneSmartBull Dec. 4 at 8:39 PM

1 · Reply

DrTim Dec. 4 at 5:33 PM

3 · Reply

ChesterKaita Dec. 4 at 5:13 PM

$VSTM News after hiurs?

0 · Reply

Consti22 Dec. 4 at 4:52 PM

$VSTM Extrem>>>

0 · Reply

sweddle Dec. 4 at 3:38 PM

$VSTM

0 · Reply

Stoltz13 Dec. 4 at 3:09 PM

$VSTM this train is leaving the station, up to you if you want to ride to double your money...

0 · Reply

Drew613 Dec. 4 at 3:05 PM

$VSTM sell the company already, Dan!

1 · Reply

MoneyGroupLLC Dec. 4 at 11:04 AM

Enter: $VSTM Calls Strike Price: $12 Expiry Date: JAN 16 2026 Buy in Price: $1.45 - $2.25 Sell Price: $2.03 Profit : +40% (Turn every $1 into $1.40) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

LiquidThetaOptions Dec. 4 at 8:21 AM

💎 LiquidTheta® Live Actionable Trade Asset: $VSTM Contracts: $VSTM January 15, 2027 $12 Calls Scale in: $2.66- $3.25 Scale out: $10.33-$17.70 Profit Potential : 139% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

Iightning Dec. 4 at 7:24 AM

1ightning® Premium Options Alert (Actionable) Ticker: $VSTM Contract: Dec 19 $11C Entry: 0.53 Exit: 0.90 Return: +70.55% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

HedgeAlerts Dec. 4 at 6:46 AM

Hedge Alert Live - Protect Your Portfolio Contract: $VSTM $10.00 Put · DEC 19, 2025 Exp Entry Price: $0.95 - $1.10 Exit Price Target: $2.25 Profit Margin: +137% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Stoltz13 Dec. 3 at 7:26 PM

$VSTM we're inevitable. $12 by end of the year.

1 · Reply

makbob5 Dec. 3 at 7:18 PM

$VSTM the $ 8 and $ 11 are good ones

0 · Reply

makbob5 Dec. 3 at 6:40 PM

$VSTM I was able to get 1/16 ‐ $9 Call sells at 2.75 today. Shows listed at 1.75, but 2.75 went through. Current stock price $10.

0 · Reply

Stoltz13 Dec. 3 at 6:12 PM

$VSTM I like the roundedness. I think we could be back running this afternoon. But first we need to get back over 10.00

0 · Reply

Stoltz13 Dec. 3 at 3:44 PM

$VSTM stronger and earlier rebound than I thought...

0 · Reply

Market Cap	671.77M
Revenue (ttm)	10.00M
Net Income (ttm)	-130.64M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,306.40%
Debt to Equity Ratio	-5.03

Volume	1,736,900
Avg Vol	2,349,498
Day's Range	N/A - N/A
Shares Out	66.78M
Stochastic %K	84%
Beta	0.41
Analysts	Strong Sell
Price Target	$16.00